

<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xmlns:xlink="https://www.w3.org/1999/xlink">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Avicenna J Med Biotech</journal-id>
      <journal-id journal-id-type="publisher-id">arij002</journal-id>
      <journal-title-group>
        <journal-title>Avicenna Journal of Medical Biotechnology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2008-2835</issn>
      <issn pub-type="epub">2008-4625</issn>
      <publisher>
        <publisher-name>Avicenna Research Institute</publisher-name>
      </publisher>
    </journal-meta>

    <article-meta>
      <article-id pub-id-type="publisher-id">ajmb70638</article-id>
      <article-id pub-id-type="doi"></article-id>
      <article-id pub-id-type="pmid"></article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
             <subject></subject> 
        </subj-group>
        <subj-group>
            <subject></subject>
        </subj-group> 
      </article-categories>
      <title-group>
        <article-title>Expression, Purification, and Application of SARS-CoV-2 Nucleocapsid Protein for  Serological Detection of IgG and IgM Antibodies</article-title>
      </title-group>
        <contrib-group><contrib contrib-type="author"><name><surname>Zamani Koukhaloo</surname><given-names>Saeideh</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Moosavi</surname><given-names>Farshid</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Zamani</surname><given-names>Bahareh</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Agharezaee</surname><given-names>Niloofar</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Yousefi</surname><given-names>Parisa</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Nazari</surname><given-names>Mahboobeh</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Mahmoudian</surname><given-names>Jafar</given-names></name></contrib><aff>Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR      , Tehran, Iran</aff></contrib-group>
      <pub-date pub-type="ppub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <pub-date pub-type="epub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <volume>18</volume>
      <issue>1</issue>
      <fpage>55</fpage>
      <lpage>60</lpage>
      <history>
        <date date-type="received">
          <day>10</day>
          <month>8</month>
          <year>2025</year>
        </date>
        <date date-type="accepted">
          <day>16</day>
          <month>10</month>
          <year>2025</year>
        </date>
      </history>
      <abstract>
      <p>
      &lt;p&gt;Background: SARS-CoV-2 is a novel coronavirus that has caused dramatic loss of life and poses an unprecedented public health challenge worldwide. The nucleocapsid (N) protein of SARS-CoV-2 is the most abundant viral protein and a potent immunogen. Methods: In the current study, the N gene of SARS-CoV-2 was amplified from RNA extracted from a COVID-19 positive patient and then cloned into the pCold-I expression vector. The full-length His-tagged N protein was expressed in Escherichia coli (E. coli) using 0.5 mM IPTG and subsequently purified by nickel affinity chromatography. The purified N protein was characterized using sodium dodecyl sulfate&amp;ndash;polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting. Furthermore, the purified N protein was applied in SARS-CoV-2 IgG and IgM ELISA immunoassays. Results: The results showed that purification of the N protein in the presence of urea yielded a protein band of approximately 48 kDa on SDS-PAGE, corresponding to the full-length N protein. Additionally, Western blot analysis of the purified recombinant N protein showed a band of the same molecular weight. In the SARS-CoV-2 IgG ELISA assay, anti-N protein antibodies from a COVID-19 positive patient&amp;rsquo;s serum successfully recognized the coated N protein. In the IgM ELISA test, an N-HRP conjugate was used in ELISA wells to reveal the interaction of HRP-conjugated N protein with pre-coated anti-N protein antibodies (IgM isotype). Conclusion: These results indicate that the expressed N protein of SARS-CoV-2 could serve as a valuable reagent for the development of antibody-based immunoassays to detect SARS-CoV-2 IgG and IgM antibodies.&lt;/p&gt;

      </p>
      </abstract>
    </article-meta>
  </front>
    
</article>
